Contrast media controversies in 2015: Imaging patients with renal impairment or risk of contrast reaction

American Journal of Roentgenology

Volumn 204, Issue 6, 2015, Pages 1174-1181

  Davenport, Matthew S ^a,b   Cohan, Richard H ^a   Ellis, James H ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Contrast; Contrast media; Contrast induced acute kidney injury (AKI); Contrast induced nephropathy (CIN); Safety

Indexed keywords

CONTRAST MEDIUM; CORTICOSTEROID; CREATININE; GADOLINIUM;

ACUTE KIDNEY FAILURE; ARTICLE; CONTRAST ENHANCEMENT; CONTRAST RADIOGRAPHY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; FUNCTIONAL ASSESSMENT; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; IMAGE RECONSTRUCTION; NEPHROGENIC SYSTEMIC FIBROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; DIAGNOSTIC USE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE BASED MEDICINE; INCIDENCE; PREVALENCE; RISK FACTOR;

ACUTE KIDNEY INJURY; CONTRAST MEDIA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; GADOLINIUM; HUMANS; INCIDENCE; PREVALENCE; RISK FACTORS;

EID: 84937691087     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.14.14259     Document Type: Article

References (99)

1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39:930-936
2. Kidney Disease Improving Global Outcomes (KDIGO). Contrast-induced AKI: definition, epidemiology, and prognosis. Kidney Int Suppl 2012; 2:69-71
3. Bruce RJ, Djamali A, Shinki K, Michel SJ, Fine JP, Pozniak MA. Background fluctuation of kidney function versus contrast-induced nephrotoxicity. AJR 2009; 192:711-718
4. Baumgarten DA, Ellis JH. Contrast-induced nephropathy: contrast material not required? AJR 2008; 191:383-386
5. Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology 2010; 258:21-28
6. Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology 2006; 239:392-397
7. Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast medium: implications for studies of contrast nephrotoxicity. AJR 2008; 191:376-382
8. McDonald RJ, McDonald JS, Carter RE, et al. Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. Radiology 2014; 273:714-725
9. McDonald JS, McDonald RJ, Carter RE, et al. Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline estimated glomerular filtration rate. Radiology 2014; 271:65-73
10. McDonald RJ, McDonald JS, Bida JP, et al. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology 2013; 267:106-118
11. McDonald JS, McDonald RJ, Comin J, et al. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology 2013; 267:119-128
12. Davenport MS, Cohan RH, Khalatbari S, et al. The challenges in assessing contrast-induced nephropathy: where are we now? AJR 2014; 202:784-789
13. Davenport MS, Khalatbari S, Cohan RH, et al. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology 2013; 268:719-728
14. Davenport MS, Khalatbari S, Dillman JR, et al. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material. Radiology 2013; 267:94-105
15. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51:1419-1428
16. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 2006; 113:1799-1806
17. Goldfarb S, McCullough PA, McDermott J, et al. Contrast-induced acute kidney injury: specialtyspecific protocols for interventional radiology, diagnostic computed tomography, and interventional cardiology. Mayo Clin Proc 2009; 84:170-179
18. McCullough PA, Adam A, Becker CR, et al.; CIN Consensus Working Panel. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006; 98:5K-13K
19. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259-2264
20. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103:368-375
21. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36:1542-1548
22. Weisbord SD, Chen H, Stone RA, et al. Associa-tions of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol 2006; 17:2871-2877
23. ACR Committee on Drugs and Contrast Media. ACR manual on contrast media, version 10 Reston, VA: 2015 (in press)
24. Stacul F, van der Molen AJ, Reimer P, et al.; Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2011; 21:2527-2541
25. Herts BR, Schneider E, Poggio ED, et al. Identifying outpatients with renal insufficiency before contrast-enhanced CT by using estimated glomerular filtration rates versus serum creatinine levels. Radiology 2008; 248:106-113
26. Davenport MS, Khalatbari S, Cohan RH, et al. Contrast medium-induced nephrotoxicity risk assessment in adult inpatients: a comparison of serum creatinine level-and estimated glomerular filtration rate-based screening methods. Radiology 2013; 269:92-100
27. Nyman U, Almen T, Jacobsson B, et al. Are intravenous injections of contrast media really less nephrotoxic than intra-arterial injections? Eur Radiol 2012; 22:1366-1371
28. Stratta P, Izzo C, Canavese C, et al. Letter to the editor re: are intravenous injections of contrast media really less nephrotoxic than intra-arterial injections? (letter) Eur Radiol 2013; 23:1260-1263
29. Vuurmans T, Byrne J, Fretz E, et al. Chronic kidney injury in patients after cardiac catheterization or percutaneous coronary intervention: a comparison of radial and femoral approaches (from the British Columbia Cardiac and Renal Registries). Heart 2010; 96:1538-1542
30. Rudnick MR, Berns JS, Cohen RM, et al. Nephrotoxic risks of renal angiography: contrast mediaassociated nephrotoxicity and atheroembolism-a critical review. Am J Kidney Dis 1994; 24:713-727
31. Kronzon I, Saric M. Cholesterol embolization syndrome. Circulation 2010; 122:631-641
32. Elicker BM, Cypel YS, Weinreb JC. IV contrast administration for CT: a survey of practices for the screening and prevention of contrast nephropathy. AJR 2006; 186:1651-1658
33. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 23:1296-1305
34. National Kidney Foundation website. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. www2.kidney. org/professionals/KDOQI/guidelines-ckd/toc.htm. Published 2002. Accessed November 26, 2014
35. U.S. Food and Drug Administration website. FDA drug safety communication: new warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. www.fda.gov/Drugs/DrugSafety/ucm223966.htm. Published December 2010. Accessed November 26, 2014
36. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation-Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470
37. Padala S, Tighiouart H, Inker LA, et al. Accuracy of a GFR estimating equation over time in people with a wide range of kidney function. Am J Kidney Dis 2012; 60:217-224
38. Kellum JA, Levin N, Bouman C, et al. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002; 8:509-514
39. Bellomo R, Ronco C, Kellum JA, et al.; Acute Dialysis Quality Initiative Group. Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs-the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-R212
40. Mehta RL, Kellum JA, Shah SV, et al.; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31
41. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473-2483
42. Yuan R, Shuman WP, Earls JP, et al. Reduced iodine load at CT pulmonary angiography with dual-energy monochromatic imaging: comparison with standard CT pulmonary angiography-a prospective randomized trial. Radiology 2012; 262:290-297
43. Kanematsu M, Goshima S, Miyoshi T, et al. Whole-body CT angiography with low tube voltage and low-concentration contrast material to reduce radiation dose and iodine load. AJR 2014; 202:[web]W106-W116
44. Nakaura T, Nakamura S, Maruyama N, et al. Low contrast agent and radiation dose protocol for hepatic dynamic CT of thin adults at 256-detector row CT: effect of low tube voltage and hybrid iterative reconstruction algorithm on image quality. Radiology 2012; 264:445-454
45. Mekan SF, Rabbani MA, Azhar-uddin M, et al. Radiocontrast nephropathy: is it dose related or not? J Pak Med Assoc 2004; 54:372-374
46. Manske CL, Sprafka JM, Strony JT, et al. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89:615-620
47. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348:491-499
48. Goldenberg I, Chonchol M, Guetta V. Reversible acute kidney injury following contrast exposure and the risk of long-term mortality. Am J Nephrol 2009; 29:136-144
49. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93:C29-C34
50. Ellis JH, Cohan RH. Prevention of contrast-induced nephropathy: an overview. Radiol Clin North Am 2009; 47:801-811
51. Rihal CS, Kashani KB. Intravascular volume expansion before primary angioplasty for prevention of acute kidney injury: hydration or dilution? Circ Cardiovasc Interv 2011; 4:405-406
52. Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet 2014; 383:1814-1823
53. Briguori C, Condorelli G. Hydration in contrastinduced acute kidney injury. Lancet 2014; 383:1786-1788
54. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162:329-336
55. Brar SS, Hiremath S, Dangas G, et al. Sodium bicarbonate for the prevention of contrast inducedacute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4:1584-1592
56. Jang JS, Jin HY, Seo JS, et al. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Circ J 2012; 76:2255-2265
57. Ellis JH, Cohan RH. Reducing the risk of contrast-induced nephropathy: a perspective on the controversies. AJR 2009; 192:1544-1549
58. Hiremath S, Akbari A, Shabana W, et al. Prevention of contrast-induced acute kidney injury: is simple oral hydration similar to intravenous? A systematic review of the evidence. PLoS ONE 2013; 8:e60009
59. Ellis JH, Cohan RH, Sonnad SS, et al. Selective use of radiographic low-osmolality contrast media in the 1990s. Radiology 1996; 200:297-311
60. McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006; 48:692-699
61. Heinrich MC, Häberle L, Müller V, et al. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology 2009; 250:68-86
62. Reed M, Meier P, Tamhane UU, et al. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2009; 2:645-654
63. From AM, Al Badarin FJ, McDonald FS, et al. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials. Circ Cardiovasc Interv 2010; 3:351-358
64. Reed MC, Moscucci M, Smith DE, et al. The relative renal safety of iodixanol and low-osmolar contrast media in patients undergoing percutaneous coronary intervention. Insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). J Invasive Cardiol 2010; 22:467-472
65. Busch SV, Jensen SE, Rosenberg J, et al. Prevention of contrast-induced nephropathy in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review. J Interv Cardiol 2013; 26:97-105
66. Solomon RJ, Natarajan MK, Doucet S, et al.; Investigators of the CARE Study. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007; 115:3189-3196
67. Dashti-Khavidaki S, Moghaddas A, Heydari B, et al. Statins against drug-induced nephrotoxicity. J Pharm Pharm Sci 2013; 16:588-608
68. Singh N, Lee JZ, Huang JJ, et al. Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population: systematic review and meta-analysis. Open Heart 2014; 1:e000127
69. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362:598-603
70. Isenbarger DW, Kent SM, O'Malley PG. Metaanalysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003; 92:1454-1458
71. Sun Z, Fu Q, Cao L, et al. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS ONE 2013; 8:e55124
72. Bagshaw SM, McAlister FA, Manns BJ, et al. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med 2006; 166:161-166
73. Biondi-Zoccai GG, Lotrionte M, Abbate A, et al. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ 2006; 332:202-209
74. Vaitkus PT, Brar C. N-acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses. Am Heart J 2007; 153:275-280
75. Van Praet JT, De Vriese AS. Prevention of contrast-induced nephropathy: a critical review. Curr Opin Nephrol Hypertens 2007; 16:336-347
76. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT). Circulation 2011; 124:1250-1259
77. Gurm HS, Smith DE, Berwanger O, et al.; BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Contemporary use and effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy among patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2012; 5:98-104
78. Yang L, Krefting I, Gorovets A, et al. Nephrogenic systemic fibrosis and class labeling of gadoliniumbased contrast agents by the Food and Drug Administration. Radiology 2012; 265:248-253
79. Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010; 31:440-446
80. Wang Y, Alkasab TK, Narin O, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011; 260:105-111
81. Altun E, Martin DR, Wertman R, et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two U.S. universities. Radiology 2009; 253:689-696
82. Thomsen HS, Stacul F. CIN: can we forget itActa Radiol 2014; 55:1027-1030
83. Thomsen HS. Gadolinium-or iodine-based contrast media: which choice? Acta Radiol 2014; 55:771-775
84. Thomsen HS. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States. Radiol Clin North Am 2009; 47:871-875
85. Thomsen HS, Morcos SK, Almén T, et al; ESUR Contrast Medium Safety Committee. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2013; 23:307-318
86. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008; 248:799-806
87. Morcos SK, Thomsen HS. Nephrogenic systemic fibrosis: more questions and some answers. Nephron Clin Pract 2008; 110:c24-c31
88. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR 2008; 190:736-741
89. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243:148-157
90. O'Malley RB, Cohan RH, Ellis JH, et al. A survey on the use of premedication prior to iodinated and gadolinium-based contrast material administration. J Am Coll Radiol 2011; 8:345-354
91. European Society of Urogenital Radiology website. ESUR Contrast Media Safety Committee. ESUR guidelines on contrast media, version 8.1. www.esur.org/guidelines/. Published 2012. Accessed November 26, 2014
92. Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media: a report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175:621-628
93. Mervak BM, Davenport MS, Ellis JH, et al. Breakthrough reaction rates in high-risk inpatients premedicated before contrast-enhanced CT. AJR 2015 (in press)
94. Wang CL, Cohan RH, Ellis JH, Caoili EM, Wang G, Francis IR. Frequency, outcome, and appropriateness of treatment of nonionic contrast media reactions. AJR 2008; 191:409-415
95. Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med 1987; 317:845-849
96. Lasser EC, Berry CC, Mishkin MM, Williamson B, Zheutlin N, Silverman JM. Pretreatment with corticosteroids to prevent adverse reactions to nonionic contrast media. AJR 1994; 162:523-526
97. Davenport MS, Cohan RH, Caoili EM, et al. Repeat contrast medium reactions in premedicated patients: frequency and severity. Radiology 2009; 253:372-379
98. Freed KS, Leder RA, Alexander C, DeLong DM, Kliewer MA. Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. AJR 2001; 176:1389-1392
99. Greenberger PA, Halwig JM, Patterson R, et al. Emergency administration of radiocontrast media in high-risk patients. J Allergy Clin Immunol 1986; 77:630-634